GlassScriptPhysician profile
Queela Tadoum
NPI 1598427809
$3,383.86
in general payments reported to CMS, 2019-2025
16 companies · $1,379 in 2025
The $1,379 reported for 2025 was more than what 83% of Psychiatric/Mental Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $244).
See the full distribution for Psychiatric/Mental Health (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $234 · 2023: $900 · 2024: $871 · 2025: $1,379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,149.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $512.40 | 2022-2025 | Rexulti, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $418.11 | 2023-2025 | Spravato, Invega Sustenna |
| Alkermes, INC. | $383.73 | 2022-2025 | Lybalvi, Aristada, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $364.76 | 2023-2025 | Caplyta |
| Abbvie INC. | $292.42 | 2023-2025 | |
| Axsome Therapeutics, INC. | $262.31 | 2024-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $250.86 | 2024 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $204.47 | 2024-2025 | Qelbree |
| Vanda Pharmaceuticals INC. | $201.11 | 2025 | Fanapt |
| Bioxcel Therapeutics, INC. | $124.65 | 2023 | Igalmi |
| Indivior INC. | $123.34 | 2023-2025 | Sublocade |
| Neurocrine Biosciences, INC. | $121.18 | 2025 | |
| Gilead Sciences, INC. | $52.41 | 2025 | Epclusa |
| Braeburn INC. | $39.27 | 2025 | Brixadi |
| Lundbeck LLC | $16.43 | 2024 | Rexulti |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $16.41 | 2024 | Uzedy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Queela Tadoum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.